Abstract
There is a growing evidence that serotoninergic systems modulate dopaminergic neurotransmission. We analyzed the association between the variations in the brain tryptophan hydroxylase 2 (TPH2) gene, a rate limiting enzyme for serotonin biosynthesis, and methamphetamine (METH) dependence/psychosis in a Japanese population. We found ten single nucleotide polymorphisms (SNPs) and two polynucleotide polymorphisms in TPH2 gene exons and exon-intron boundaries. A total of 162 patients and 243 controls were used for the association analysis between these polymorphisms and METH dependence/psychosis. No significant differences were observed in either genotypic or allelic frequencies between METH dependent/psychotic patients and controls. A global test of differentiation among samples based on haplotype frequencies showed no significant association. With respect to latency of psychosis, prognosis of psychosis, and spontaneous relapse, we found no significant association with these SNPs. These results suggest that the TPH2 gene variants may not be a factor in vulnerability to METH dependence/psychosis.
Keywords: Single nucleotide polymorphism, SNP, variation, serotonin, human, Japanese, MAP, abuse, polymorphism, AP, nucleotide polymorphisms, polymorphic variants
Current Neuropharmacology
Title: Association Analysis of the Tryptophan Hydroxylase 2 Gene Polymorphisms in Patients with Methamphetamine Dependence/Psychosis
Volume: 9 Issue: 1
Author(s): Hideaki Kobayashi, Hiroshi Ujike, Nakao Iwata, Toshiya Inada, Mitsuhiko Yamada, Yoshimoto Sekine, Naohisa Uchimura, Masaomi Iyo, Norio Ozaki, Masanari Itokawa and Ichiro Sora
Affiliation:
Keywords: Single nucleotide polymorphism, SNP, variation, serotonin, human, Japanese, MAP, abuse, polymorphism, AP, nucleotide polymorphisms, polymorphic variants
Abstract: There is a growing evidence that serotoninergic systems modulate dopaminergic neurotransmission. We analyzed the association between the variations in the brain tryptophan hydroxylase 2 (TPH2) gene, a rate limiting enzyme for serotonin biosynthesis, and methamphetamine (METH) dependence/psychosis in a Japanese population. We found ten single nucleotide polymorphisms (SNPs) and two polynucleotide polymorphisms in TPH2 gene exons and exon-intron boundaries. A total of 162 patients and 243 controls were used for the association analysis between these polymorphisms and METH dependence/psychosis. No significant differences were observed in either genotypic or allelic frequencies between METH dependent/psychotic patients and controls. A global test of differentiation among samples based on haplotype frequencies showed no significant association. With respect to latency of psychosis, prognosis of psychosis, and spontaneous relapse, we found no significant association with these SNPs. These results suggest that the TPH2 gene variants may not be a factor in vulnerability to METH dependence/psychosis.
Export Options
About this article
Cite this article as:
Kobayashi Hideaki, Ujike Hiroshi, Iwata Nakao, Inada Toshiya, Yamada Mitsuhiko, Sekine Yoshimoto, Uchimura Naohisa, Iyo Masaomi, Ozaki Norio, Itokawa Masanari and Sora Ichiro, Association Analysis of the Tryptophan Hydroxylase 2 Gene Polymorphisms in Patients with Methamphetamine Dependence/Psychosis, Current Neuropharmacology 2011; 9 (1) . https://dx.doi.org/10.2174/157015911795017335
DOI https://dx.doi.org/10.2174/157015911795017335 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Amendatory Effect of Flavonoids in Alzheimer's Disease Against Mitochondrial Dysfunction
Current Drug Targets LHON: Mitochondrial Mutations and More
Current Genomics Prevention of Macrovascular Disease in Type 2 Diabetic Patients: Blockade of the Renin-Angiotensin-Aldosterone System
Current Diabetes Reviews The Pathogenic Role of Persistent Milk Signaling in mTORC1- and Milk- MicroRNA-Driven Type 2 Diabetes Mellitus
Current Diabetes Reviews Editorial [Hot Topic: Recent Discoveries in the Search for Novel Antidepressants and Anxiolytics (Executive Editors: D. Bleakman and D. Gehlert)]
Current Pharmaceutical Design The Prediction of Human Intestinal Absorption Based on the Molecular Structure
Current Drug Metabolism Radiotracers in Oncology
Current Radiopharmaceuticals TRAIL: A Sword for Killing Tumors
Current Medicinal Chemistry Mesenchymal Stem Cells: New Approaches for the Treatment of Neurological Diseases
Current Stem Cell Research & Therapy Computational and Experimental Approaches to Design Inhibitors of Amylin Aggregation
Current Drug Targets Chronic Inflammation and Cancer: The Role of Endothelial Dysfunction and Vascular Inflammation
Current Pharmaceutical Design Differential Effects of Nicotine Exposure on the Hippocampus Across Lifespan
Current Neuropharmacology Lipid-based Nano-phytomedicines for Disease Treatment and Theranostic Applications
Current Nanomedicine Olanzapine-Induced Reversible Pellagroid Skin Lesion
Current Drug Safety Simultaneous Interruption of Signal Transduction and Cell Cycle Regulatory Pathways: Implications for New Approaches to the Treatment of Childhood Leukemias
Current Drug Targets The Added Value of Liquid Antipsychotics: The Case of Quetiapine
Current Clinical Pharmacology Physical Therapy Modalities in Management of Fibromyalgia
Current Pharmaceutical Design Oxidative Stress in Alzheimer Patients in Different Stages of the Disease
Current Medicinal Chemistry Oxidative stress and myocarditis
Current Pharmaceutical Design Sepsis-induced Cardiomyopathy
Current Cardiology Reviews